FasL gene knock-down therapy enhances the antiglioma immune response

Neuro-Oncology

Volumn 12, Issue 5, 2010, Pages 482-489

  Jansen, Timothy ^a   Tyler, Betty ^a   Mankowski, Joseph L ^c   Recinos, Violette Renard ^a   Pradilla, Gustavo ^a   Legnani, Federico ^a,b   Laterra, John ^a,c   Olivi, Alessandro ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CD95L; Fas ligand; Glioma; Immunity; Immunotherapy

Indexed keywords

FAS LIGAND; PHYTOHEMAGGLUTININ; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CELL INTERACTION; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKEMIA CELL LINE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; T LYMPHOCYTE; TUMOR GROWTH; ANIMAL; BRAIN TUMOR; DRUG SCREENING; FISCHER 344 RAT; GENE SILENCING; GENE THERAPY; GENETICS; IMMUNOBLOTTING; IMMUNOLOGY; METHODOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ESCAPE;

ANIMALS; BRAIN NEOPLASMS; FAS LIGAND PROTEIN; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; GLIOMA; HUMANS; IMMUNOBLOTTING; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954741566     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop052     Document Type: Article

References (30)

1. Stupp R, Pavlidis N, Jelic S; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol. 2005;16(suppl 1):i64-i65
2. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66(11):5527-5536
3. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncology. 1993;4:493-540
4. Markowitz S, Roberts A. Tumor suppressor activity of the TGF-b pathway in human cancers. Cytokine Growth Factor Rev. 1996;7:93-102
5. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer (published online ahead of print April 15, 2002). Annu Rev Genomics Hum Genet. 2002;3:101-128. Review
6. Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function (published online ahead of print December 03, 2007). Cytokine Growth Factor Rev. 2008;19(1):65-77. Review
7. Larmonier N, Marron M, Zeng Y, et al. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother. 2007; 56:48-59
8. Hattori E, Okumoto K, Adachi T, et al. Possible contribution of circulating interleukin-10 (IL-10) to antitumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol Res. 2003;27:309-314
9. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? Clin Invest. 1997;99(6):1173-1178
10. Gratas C, Tohma Y, Van Meir EG, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1997;7(3):863-869
11. Song E, Chen J, Ouyang N, et al. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer. 2001;85(7): 1047-1054
12. Ashley DM, Kong FM, Bigner DD, et al. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res. 1998;58(2):302-309
13. Yang BC, Lin HK, Hor WS, et al. Mediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by Fas signaling through a protein kinase A-independent pathway. J Immunol. 2003;171(8):3947-3954
14. Griffith S, Brunner T, Fletcher S, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science.1995;270(5239):189-1192
15. Ferguson TA, Griffith TS. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy. 2007;92:140-154. Review
16. Bodmer D, Brors D, Pak K, et al. Inflammatory signals increase Fas ligand expression by inner ear cells. J Neuroimmunol. 2002; 129(1-2):10-17
17. Zhang B, Sun T, Xue L, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer (published online ahead of print December 20, 2006). Carcinogenesis. 2007;28(5):1067-1073
18. Minas V, Rolaki A, Kalantaridou SN, et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation (published online ahead of print July 31, 2007). Br J Cancer. 2007; 97(5):637-645
19. Towbin H, Ozbey O, Zingel O. An immunoblotting method for highresolution isoelectric focusing of protein isoforms on immobilized pH gradients. Electrophoresis. 2001;22(10):1887-1893
20. Reznik TE, Sang Y, Ma Y, et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res. 2008;6(1):139-150
21. Posmantur R, Wang KK, Gilbertsen RB. Caspase-3-like activity is necessary for IL-2 release in activated Jurkat T-cells. Exp Cell Res. 1998;244(1):302-309
22. Tamargo RJ, Myseros JS, Epstein JI, et al. Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res. 1993;53:329-333
23. Kovar JL, Johnson MA, Volcheck WM, et al. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol. 2006;169(4):1415-1426
24. Xia S, Rosen EM, Laterra J. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress. Cancer Res. 2005;65(12):5248-5256
25. Giraud S, Bessette B, Boda C, et al. In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats. Int J Oncolog. 2007;30:273-281
26. Wei J, deAngulo G, Sun W, et al. Topotecan enhances immune clearance of gliomas (published online ahead of print July 02, 2008). Cancer Immunol Immunother. 2009;58(2):259-270
27. Didenko VV, Ngo HN, Minchew C, Baskin DS. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg. 2002;96(3):580-584
28. Herzer K, Hofmann TG, Teufel A, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocyticleukemia protein and TRAIL independently of p53. Cancer Res. 2009;69(3):855-862
29. Bertoli C, Copetti T, Lam EW, et al. Calpain small-1 modulates Akt/ FoxO3A signaling and apoptosis through PP2A. Oncogene. 2008;28: 721-733
30. Nam M, Johnston P, Lal B, Indurti R, Wilson MA, Laterra J. Endothelial cell-based cytokine gene delivery inhibits 9L glioma growth in vivo. Brain Res. 1996;731(1-2):161-170